Short answer
NovoCure Ltd (NVCR) filed its Q3 2025 10-Q quarterly report on Oct 30, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $167M (up 7.8% year over year) with net income of −$37M.
Q3 2025 key financials · XBRL
- Revenue
- $167M
- +7.8% YoY · +5.3% QoQ
- Net income
- −$37M
- −21.9% YoY · +7.1% QoQ
- Operating margin
- -21.5%
- Gross margin
- 73.2%
- EPS (diluted)
- −$0.33
- −17.9% YoY · +8.3% QoQ
Source: XBRL data from the NovoCure Ltd (NVCR) Q3 2025 10-Q on SEC EDGAR. USD.
NovoCure Ltd Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes to risk factors since last 10-K filing
- Regulatory risk from ongoing SEC reporting compliance and potential updates to forward-looking statements
- Operational risk tied to trademark use and intellectual property protection for Optune Gio® and Optune Lua®
- Market risk linked to product branding and acceptance impacting sales of Optune platforms
- Financial risk related to compliance costs associated with maintaining SEC reporting standards
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other NovoCure Ltd quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.